Your fact-checks

Your fact-checks will appear here

factually
Support us
  • Home
  • Politics
  • Business
  • Society
  • Technology
  • Health
  • Science
  • Entertainment
Index/Topics/NCT03628079 Trial

NCT03628079 Trial

GI cancer trial with mebendazole, including individualized dosing and safety monitoring.

Fact-Checks

1 result
Feb 6, 2026

What are the full hematologic monitoring schedules (CBC frequency and stopping rules) used in registered mebendazole oncology trials (NCT01729260, NCT01837862, NCT03628079)?

The public record for the three contains explicit hematologic toxicity definitions for the adult high‑grade glioma Phase I trial () but does not publish a complete, day‑by‑day CBC monitoring schedule ...

About
Blog
Contact
FAQ
Terms & ConditionsTerms
Privacy PolicyPrivacy
Manage data